Who could replace Sir Andrew Dillon at NICE?

With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health

After two decades taking on pharma over price, Sir Andrew Di...

After more than 20 years of challenging pharma over drug prices, Sir Andrew Dillon is to step down as NICE’s chief executive next year.

NICE’s track record in cancer drugs: the impact of the CDF a...

Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 and CDF 2.0 to explore it's success.

MSD’s Keytruda plus chemo backed by NICE for lung cancer

NICE backs Bayer's Xarelto in new stroke and heart attack pr...

Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults with coronary artery disease, NICE has said.

NICE expands funding for AstraZeneca's high potassium drug

NICE has recommended extended funding on the NHS for AstraZeneca’s high potassium drug Lokelma in final draft guidance.